Trials / Recruiting
RecruitingNCT04918186
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Detailed description
This study is being conducted to determine if this approach is better or worse than the standard of care for ovarian cancer. The standard of care is defined as care most people get for ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab | 1500mg IV, 60 min day 1 every 4 weeks |
| DRUG | BA3011 | IV |
| DRUG | BA3021 | IV |
| DRUG | ENB003 | IV |
| DRUG | Toripalimab | IV |
Timeline
- Start date
- 2022-05-03
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
- First posted
- 2021-06-08
- Last updated
- 2026-02-12
Locations
7 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04918186. Inclusion in this directory is not an endorsement.